Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Orthod ; 17(5): 385-94, 1995 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8529751

RESUMO

TMJ involvement in children with Juvenile Chronic Arthritis (JCA) will frequently cause disturbance of the growth of the mandible. Orthodontic treatment of these patients often includes orthognathic surgery, and are complicated to handle with respect to the damaged joint and impaired function. The aim of this presentation is to suggest an early treatment with a functional splint appliance, a distraction splint, with the purpose of increasing function of the joint and ensuring continuous growth of the mandible.


Assuntos
Artrite Juvenil/fisiopatologia , Má Oclusão/terapia , Mandíbula/crescimento & desenvolvimento , Côndilo Mandibular/fisiopatologia , Aparelhos Ortodônticos Funcionais , Artrite Juvenil/complicações , Reabsorção Óssea/complicações , Reabsorção Óssea/fisiopatologia , Criança , Feminino , Humanos , Má Oclusão/complicações , Má Oclusão/cirurgia , Côndilo Mandibular/crescimento & desenvolvimento , Placas Oclusais , Desenho de Aparelho Ortodôntico , Retrognatismo/complicações , Retrognatismo/terapia , Transtornos da Articulação Temporomandibular/complicações , Transtornos da Articulação Temporomandibular/fisiopatologia
2.
J Clin Pharmacol ; 31(5): 477-83, 1991 May.
Artigo em Inglês | MEDLINE | ID: mdl-1828811

RESUMO

The synthetic retinoic acid derivative acitretin has recently been introduced for the treatment of severe psoriasis. Hitherto, the use of the carboxylic acid ester analogue, etretinate, has been hampered by an extremely long elimination half-life of up to 120 days for this drug. In the presented study, 12 patients with severe psoriasis were treated with 30 mg acitretin daily for a period of 6 months. The maximum plasma concentration of the drug occurred within about 0.9 to 4.6 hours with an apparent absorption half-life ranging from 0.2 to 1.7 hours and with half-lives of the distribution phase within the range of 1.2 to 3.5 hours. After stopping therapy, the terminal elimination half-life of acitretin varied between 16.5 and 111.1 hours (mean: 47.1 hr +/- 29.8 SD), whereas that for the 13-cis-metabolite varied between 36.5 and 249.4 hours (mean: 119.4 hr +/- 73.4 SD). Suction blister fluid concentrations of both the parent drug and metabolite were lower than plasma concentrations. The mean concentration of serum triglycerides was significantly elevated during the course of therapy, but still remained within the normal range. Saliva concentrations of drug and metabolite at steady-state were below 1 ng/mL. It is not possible from the observed half-lives of acitretin and its 13-cis-metabolite to draw any definite conclusion with regard to the anticonceptional period after acitretin therapy in psoriatic patients.


Assuntos
Psoríase/metabolismo , Tretinoína/análogos & derivados , Acitretina , Adulto , Vesícula/metabolismo , Feminino , Meia-Vida , Humanos , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Psoríase/tratamento farmacológico , Saliva/química , Tretinoína/administração & dosagem , Tretinoína/farmacocinética , Tretinoína/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...